Capsule Summary Slidesets

Share

Program Content

Activities

  • DESTINY-Lung01
    Phase II DESTINY-Lung01: Interim Analysis of Trastuzumab Deruxtecan in Patients With HER2-Mutated NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 30, 2020

    Expires: May 29, 2021

  • KEYNOTE-604
    KEYNOTE-604 Final Analysis: Addition of Pembrolizumab to Etoposide and Platinum in Extensive-Stage SCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 01, 2020

    Expires: May 31, 2021

  • CASPIAN
    CASPIAN: Phase III Study of First-line Durvalumab + Tremelimumab + EP vs Durvalumab + EP vs EP Alone in Extensive-Stage SCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 01, 2020

    Expires: May 31, 2021

  • ADAURA: Adj Osimertinib
    Phase III ADAURA: Adjuvant Osimertinib vs Placebo After Complete Resection in Patients With Stage IB-IIIA EGFR-Mutated NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 01, 2020

    Expires: May 31, 2021

  • CheckMate 227: 3-Year Update
    First-line Nivolumab Plus Ipilimumab vs Chemotherapy in Advanced NSCLC: 3-Year Update of CheckMate 227 Part 1
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 01, 2020

    Expires: May 31, 2021

  • CheckMate 9LA
    CheckMate 9LA: Nivolumab and Ipilimumab Plus 2 Cycles of Platinum-Doublet Chemotherapy vs 4 Cycles Chemotherapy as First-line Treatment for Advanced Non-small Cell Lung Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 02, 2020

    Expires: June 01, 2021

  • RESILIENT: Liposomal Irinotecan
    RESILIENT Part 1: Phase II Study of Liposomal Irinotecan After Platinum Chemotherapy in Small-Cell Lung Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2020

    Expires: June 02, 2021

  • Lurbinectedin Plus Irinotecan
    Phase Ib/II Trial of Lurbinectedin Plus Irinotecan in Patients With Advanced Solid Tumors
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2020

    Expires: June 03, 2021

  • GEOMETRY: Capmatinib in METamp+ NSCLC
    Phase II GEOMETRY mono-1: Capmatinib in Patients With NSCLC and High MET Amplification
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2020

    Expires: June 03, 2021

  • CITYSCAPE: Tiragolumab
    Phase II CITYSCAPE: Addition of Tiragolumab, an Anti-TIGIT Antibody, to First-line Atezolizumab in PD-L1–Selected Metastatic NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2020

    Expires: June 04, 2021

  • SINDAS Interim Analysis
    Phase III SINDAS: Interim Analysis of First-line EGFR TKI With vs Without SBRT in Patients With EGFR-Mutated Oligometastatic NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2020

    Expires: June 04, 2021

  • ARROW: Pralsetinib in <i>RET</i>+ NSCLC
    Phase I/II ARROW: Registrational Dataset of RET Inhibitor Pralsetinib (BLU-667) in Patients With Advanced RET Fusion–Positive NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2020

    Expires: June 07, 2021

  • ADJUVANT-CTONG 1104
    ADJUVANT-CTONG 1104: Final OS Analysis of Phase III Study of Adjuvant Gefitinib vs Chemotherapy in Chinese Patients With Resected EGFR-Mutated NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2020

    Expires: June 08, 2021

Provided by

ProCE Banner

Supporters

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc.

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono